These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
451 related articles for article (PubMed ID: 25640208)
1. What goes up must come down: biomarkers and novel biologicals in severe asthma. Hilvering B; Pavord ID Clin Exp Allergy; 2015 Jul; 45(7):1162-9. PubMed ID: 25640208 [TBL] [Abstract][Full Text] [Related]
2. Biologic and New Therapies in Asthma. Tabatabaian F; Ledford DK; Casale TB Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480 [TBL] [Abstract][Full Text] [Related]
3. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. Fajt ML; Wenzel SE J Allergy Clin Immunol; 2015 Feb; 135(2):299-310; quiz 311. PubMed ID: 25662302 [TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy for Severe Asthma: Identifying the Right Patients. Low K; Bardin PG Mol Diagn Ther; 2017 Jun; 21(3):235-247. PubMed ID: 28044257 [TBL] [Abstract][Full Text] [Related]
5. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. Chung KF J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339 [TBL] [Abstract][Full Text] [Related]
6. Emerging Biologics in Severe Asthma. Pavord ID; Hilvering B; Shrimanker R Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629 [TBL] [Abstract][Full Text] [Related]
7. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004 [TBL] [Abstract][Full Text] [Related]
8. Patient stratification and the unmet need in asthma. Swedin L; Saarne T; Rehnberg M; Glader P; Niedzielska M; Johansson G; Hazon P; Catley MC Pharmacol Ther; 2017 Jan; 169():13-34. PubMed ID: 27373855 [TBL] [Abstract][Full Text] [Related]
9. Different endotypes and phenotypes drive the heterogeneity in severe asthma. McDowell PJ; Heaney LG Allergy; 2020 Feb; 75(2):302-310. PubMed ID: 31267562 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies for the treatment of refractory asthma. Hambly N; Nair P Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927 [TBL] [Abstract][Full Text] [Related]
17. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. Moss RB Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714 [TBL] [Abstract][Full Text] [Related]
19. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? De Ferrari L; Chiappori A; Bagnasco D; Riccio AM; Passalacqua G; Canonica GW Expert Rev Respir Med; 2016; 10(1):29-38. PubMed ID: 26566089 [TBL] [Abstract][Full Text] [Related]
20. From phenotypes to endotypes to asthma treatment. Agache IO Curr Opin Allergy Clin Immunol; 2013 Jun; 13(3):249-56. PubMed ID: 23587683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]